Albireo enrolls first patient in phase 3 clinical trial of odevixibat in biliary atresia

Albireo enrolls first patient in phase 3 clinical trial of odevixibat in biliary atresia.albireo pharma inc - trial expands odevixibat's development program into second rare cholestatic liver disease.albireo pharma - finalizing a third pivotal trial of odevixibat in alagille syndrome and anticipates initiating trial by end of 2020.
ALBO Ratings Summary
ALBO Quant Ranking